Shares of Tesaro Inc. (Nasdaq: TSRO) stock were up 23% today (Monday) after the company announced that its drug rolapitant met the main goal of its third and final Phase 3 trial.
According to Money Morning's BioScience Investment Specialist Ernie Tremblay, volatility like that of TSRO stock is common among biotech companies with late stage drug candidates.